Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 2;110(7):1778-84.
doi: 10.1038/bjc.2014.71. Epub 2014 Mar 4.

Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

A Saroufim  1 , Y Messai  2 , M Hasmim  2 , N Rioux  3 , R Iacovelli  4 , G Verhoest  3 , K Bensalah  3 , J-J Patard  5 , L Albiges  1 , B Azzarone  6 , B Escudier  1 , S Chouaib  2
Affiliations

Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

A Saroufim et al. Br J Cancer. .

Abstract

Background: Angiogenesis is essential for tumour growth and metastasis. There are conflicting reports as to whether microvessel density (MVD) using the endothelial marker CD105 (cluster of differentiation molecule 105) in clear-cell renal cell carcinomas (ccRCC) is associated with prognosis. Recently, CD105 has been described as a RCC cancer stem cell marker.

Methods: A total of 102 ccRCC were analysed. Representative tumour sections were stained for CD105. Vascularity (endothelial CD105) was quantified by MVD. The immunohistochemistry analysis detected positive (if present) or negative (if absent) CD105 tumoral staining. This retrospective population-based study was evaluated using Kaplan-Meier method, t-test and Cox proportional hazard model.

Results: We found that the expression of endothelial CD105 (MVD) negatively correlated with nuclear grade (P<0.001), tumour stage (P<0.001) and Leibovitch score (P<0.001), whereas the expression of tumoral CD105 positively correlated with these three clinicopathological factors (P<0.001). In multivariate analysis, tumoral CD105 was found to be an independent predictor of poor overall survival (P=0.002).

Conclusions: We have shown for the first time that tumoral CD105 is an independent predictive marker for death risk and unfavourable prognosis in patients with ccRCC after curative resection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient characteristics. (A). Patient characteristics (B). Overall survival of stage I–III patients versus stage IV patients (C). Overall survival of low-grade patients versus high-grade patients.
Figure 2
Figure 2
Endothelial CD105 expression. (A). Representative examples of (1) low-, (2) moderate- and (3) high-immunohistochemistry expression of endothelial CD105 on tumoral tissues. (B). Associations of endothelial CD105 expression and tumour characteristics (grade, stage and Leibovitch) in the entire cohort. (C–D). Kaplan–Meier estimates of 5-year OS (C) and DFS (D) according to endothelial CD105 expression in non-metastatic patients. ***P<0.001.
Figure 3
Figure 3
Tumoral CD105 expression. (A). Immunohistochemical images of four cases with tumours denoted as having (2-3-4) tumoral CD105 or not (1). (B). Correlations between the presence of tumoral CD105 by immunochemistry and tumor characteristics (grade, stage and Leibovitch) in the entire cohort. (C–D). Kaplan–Meier estimates of 5-year OS (C) and DFS (D) according to the presence or the absence of tumoral CD105 in non-metastatic patients. ***P<0.001.
See this image and copyright information in PMC

References

    1. Albiges L, Salem M, Rini B, Escudier B. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am. 2011;25 (4:813–833. - PubMed
    1. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995;87 (21:1603–1612. - PubMed
    1. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J. 2008;22 (10:3696–3705. - PubMed
    1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353 (23:2477–2490. - PubMed
    1. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, Ellis LM. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14 (7:1931–1937. - PubMed

Publication types

MeSH terms

LinkOut - more resources